

30th May, 2026

To,  
The Bombay Stock Exchange Ltd.  
P.J Towers, Dalal Street,  
Mumbai- 400 001.

Ref: Script Code: - 519471, Script ID: - AMBARPIL

Dear Sir

**Subject: Outcome of the Board Meeting held on Friday, May 30, 2026 and submission of Audited Financial Results (Standalone) for the Quarter and Year ended March 31, 2026**

We wish to inform you that Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations, 2015"), the Board of Directors of the Company at its meeting held on today 30th May, 2026 at 3:30 PM and concluded at 4:15 PM the Board of Directors of the Company has considered and approved:


1. The Audited Financial Result for the Quarter and Year ended on 31st March 2026.
2. Re- Appointed Rajendra Natverlal Shah & Co. FRN No. 0130209W as an internal Auditor of the Company for FY 2026-27.
3. Approved Related Party Transactions with Ankur Oil Industries with respect of Sale of Goods and job work subject to approval of Shareholder.

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, We enclosed the following:

1. Audited Standalone Financial Results of the Company for the Quarter and Financial year ended March 31, 2026 and along with Auditor's Report thereon, submitted by Statutory Auditors;
2. Declaration on Unmodified Opinion on Auditors' Report under Regulations 33(3)(d) of SEBI LODR Regulations, 2015 attached as Annexure-1;
3. Details as per SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 relating to the Appointment/Re-appointment of Directors / Key Managerial Personnel/Auditor of the Company is attached as Annexure-2;

You are requested to kindly take the same on record.

Thanking & Regards,

AMBAR PROTEIN INDUSTRIES LIMITED  
  
M. M. MENTA  
COMPANY SECRETARY



Plot No: 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand,  
Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

GSTIN No.: 24AABCM0541N1ZM | PAN No.: AABCM0541N | CIN No.: L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction

30<sup>th</sup> May, 2026

To,  
The Bombay Stock Exchange Ltd.  
P.J Towers,  
Dalal Street,  
Mumbai- 400 001.

Ref: Script Code: - 519471, Script ID: - AMBARPIL

## DECLARATION


SUB: DECLARATION UNDER REGULATION 33(3)(D) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION, 2015 AND SEBI CIRCULAR NO. CIR/CFD/CMD/56/2016.

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby confirm and declare that the Statutory Auditor of the Company, M/s. Fenil P Shah and Associates., Chartered Accountants, have issued the Audit Report with **Unmodified opinion** in respect of the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026.

You request you to take the same on record.

Thanking you,

FOR, AMBAR PROTEIN INDUSTRIES LIMITED  
  
PRADEEP C. KHETANI  
MANAGING DIRECTOR



Plot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand,  
Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

GSTIN No.: 24AABCM0541N1ZM | PAN No.: AABCM0541N | CIN No.: L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction

1. Reappointment of Internal Auditor:

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1.	Name of the Internal Auditor	Rajendra Natverlal Shah & Co. FRN No. 0130209W
2.	Reason of Change	Re-Appointment as Internal Auditor
3.	Date of Appointment	Date: 30-05-2026, For 2026-27
4.	Brief Profile	Rajendra Natverlal Shah & Co. FRN No. 0130209W working for more than 40 years in the field of GST Audit, Income Tax Audit, Stock Audit and Internal Audit, Concurrent Audit, providing consultancy in GST, Income Tax etc.
5.	Disclosure of relationships between Directors	Not Applicable



Plot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand, Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

**GSTIN No.:** 24AABCM0541N1ZM | **PAN No.:** AABCM0541N | **CIN No.:** L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction



Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors of  
Ambar Protein Industries Limited

**Report on the audit of the Standalone Financial Results**

**Opinion :**

1. We have audited the accompanying statement of Standalone Quarterly and year to date Financial Results of Ambar Protein Industries Limited ("the company") for the Quarter Ended March 31, 2026 and the year to date results for the period from April 01, 2025 to March 31, 2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended March 31, 2026 as well as the year to date results for the period from April 01, 2025 to March 31, 2026.

**Basis for Opinion :**

2. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

3. These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the audited standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the statement that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard

+91 85119 10789

office@cafenil.in

www.cafenil.in

1303, Yash Anant, Opp. Old RBI, Ashram Road, Ahmedabad - 380 009





34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

4. Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for Our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our





auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

5. The statement includes the results for the quarter ended 31st March 2026 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures up to the nine months of the current financial year, which were subject to limited review by us.

Our report on the statement is not modified in respect of this matter

For, **Fenil P. Shah and Associates**  
Chartered Accountant

FENIL  
PARESH  
SHAH

Digitally signed  
by FENIL PARESH  
SHAH  
Date: 2026.05.30  
15:27:48 +05'30'

**Fenil P Shah**  
Proprietor  
Mem. No.: 141088  
FRN No.: 143571W  
Place: AHMEDABAD  
Date: 30/05/2026  
UDIN: 26141088PTBDGZ3800



**AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2026**

(Amount in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	Audited	UnAudited	Audited	Audited	Audited
<b>1 Income</b>					
(a) Revenue from operations	14,679.97	12,491.97	12,780.87	50,065.59	42,162.30
(b) Other Income	21.87	18.65	20.49	78.12	84.16
<b>1A Total Income</b>	<b>14,701.83</b>	<b>12,510.62</b>	<b>12,801.36</b>	<b>50,143.72</b>	<b>42,246.47</b>
<b>2 Expenses :</b>					
(a) Cost of Material consumed	15,130.54	11,907.25	12,631.25	48,776.77	39,502.46
(b) Purchases stock -in- trade	-	0.43	-	0.43	-
(c) Changes in Inventories Finished Goods, Work -in-progress and stock-in-trade	(1,168.40)	(8.69)	(549.57)	(980.72)	43.12
(d) Employee Benefits expenses	62.78	62.36	44.60	236.04	171.10
(e) Finance Cost	54.75	50.31	57.97	202.96	226.76
(f) Depreciation, amortization, impairment and obsolescence	35.50	34.02	21.11	136.74	131.11
(g) Other expenses	243.62	206.31	276.30	832.91	868.80
<b>2A Total expenses</b>	<b>14,358.80</b>	<b>12,251.99</b>	<b>12,481.66</b>	<b>49,205.13</b>	<b>40,943.36</b>
<b>3 Profit / (loss) before exceptional items and tax (1A - 2A)</b>	<b>343.03</b>	<b>258.63</b>	<b>319.70</b>	<b>938.59</b>	<b>1,303.11</b>
4 Exceptional Item	-	-	-	-	-
<b>5 Profit / (loss) before tax (3-4)</b>	<b>343.03</b>	<b>258.63</b>	<b>319.70</b>	<b>938.59</b>	<b>1,303.11</b>
<b>6 Tax Expense</b>					
a) Current Tax	81.25	66.43	86.13	233.60	330.50
b) Earlier year tax Adjustments	(0.84)	5.59	-	4.74	6.73
b) Deferred Tax	16.21	5.18	(14.90)	(2.41)	0.86
<b>Total Tax Expense</b>	<b>96.62</b>	<b>77.20</b>	<b>71.23</b>	<b>235.93</b>	<b>338.09</b>
<b>7 Net Profit / (loss) for the period (PAT) (5-6)</b>	<b>246.41</b>	<b>181.43</b>	<b>248.47</b>	<b>702.66</b>	<b>965.02</b>
8 Other Comprehensive Income (OCI)	1.65	0.21	1.16	2.29	0.95
Tax on above	0.42	0.05	0.29	0.58	0.21
<b>9 Total Comprehensive Income for the period (7+8)</b>	<b>247.64</b>	<b>181.70</b>	<b>249.33</b>	<b>704.37</b>	<b>965.66</b>
10 Paid - up equity share capital ( face value of share : Rs 10 each)	575.00	575.00	575.00	575.00	575.00
<b>11 Earnings per share (EPS) of Rs 10 each ( Not annualised ) :</b>					
(a) Basic EPS (Rs.)	4.29	3.16	4.32	12.22	16.78
(b) Diluted EPS (Rs.)	4.29	3.16	4.32	12.22	16.78

**NOTES:**

- These financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter and other accounting principles generally accepted in India.
- The Audit Committee reviewed the above results. The Board of Directors in their meeting held on 30th May, 2026 approved the above results.
- These result has been audited by the Statutory Auditor of the company who has issued an unmodified audit report on the standalone annual financial statement for the year ended 31st March, 2026.
- The Company has only one business segment i.e. Manufacturing and selling of Edible Oil.
- Figures for the previous year have been regrouped, recast and rearranged, wherever necessary.
- The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective Financial year, also the result at the end of the third quarter were only reviewed and not subject to Audit.

By Order of Board of Directors

Place: Ahmedabad  
Date: 30.05.2026

  
**AMBAR PROTEIN INDUSTRIES LIMITED**  
AHMEDABAD  
PRADEEP KHETANI  
MANAGING DIRECTOR



Plot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand, Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

**GSTIN No.:** 24AABCM0541N1ZM | **PAN No.:** AABCM0541N | **CIN No.:** L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction

## BALANCE SHEET AS ON 31.03.2026

(Amount in lakhs)

Particular	As at 31.03.2026	As at 31.03.2025
	Audited	Audited
<b>1 ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	1,832.54	1,841.12
(b) Capital work- in- progress	103.35	74.98
(d) Financial Assets	-	-
(i) Investments	2.00	2.00
(ii) Trade receivables	-	-
(iii) Loans	-	-
(iv) Other Non-Current Financial Assets	15	14.97
(e) Deferred tax assets (net)	327.23	283.35
(f) Other non-current assets	-	-
<b>Total Non-Current Assets</b>	<b>2,280.23</b>	<b>2,216.42</b>
<b>2 Current assets</b>		
(a) Inventories	3,867.11	2,042.77
(b) Financial Assets		
(i) Investments	1,017.57	2,027.76
(ii) Trade receivables	122.94	113.10
(iii) Cash and cash equivalents	7.63	7.54
(iv) Bank balances other than (iii) above	1.71	0.20
(v) Loans	-	-
(vi) Other	-	-
(c) Current Tax Assets (Net)	905.46	642.57
(d) Other current assets	-	-
<b>Total Current Assets</b>	<b>5,922.43</b>	<b>4,833.95</b>
<b>Total Asset</b>	<b>8,202.66</b>	<b>7,050.38</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	575.00	575.00
(b) Other Equity	3,601.88	2,897.51
<b>Total Equity</b>	<b>4,176.88</b>	<b>3,472.51</b>
<b>LIABILITIES</b>		
<b>1 Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	12.96	16.32
(ii) Trade payables	-	-
(iii) Other Financial liabilities	-	-
(b) Provisions	28.83	31.51
(c) Deferred tax liabilities	202.72	205.14
(d) Other non-current liabilities	-	-
<b>Total Non-Current Liabilities</b>	<b>244.51</b>	<b>252.96</b>
<b>2 Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	2,579.29	2,579.28
(ii) Trade payables		
Total outstanding dues of MSME	155.26	97.23
Total outstanding dues of other than MSME	737.31	267.02
(iii) other financial liabilities	-	-
(b) other current liabilities	40.21	28.81
(c) Provisions	35.02	21.86
(d) Current Tax Liabilities (Net)	234.17	330.71
<b>Total Current Liabilities</b>	<b>3,781.27</b>	<b>3,324.91</b>
<b>Total Equity and liabilities</b>	<b>8,202.66</b>	<b>7,050.38</b>



Plot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Tal. Gandhinagar, Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
Place: Ahmedabad E: ambarprotein@gmail.com | W: www.ambarprotein.com

Date: 30/05/2026  
GSTIN No.: 24AABCM0541N1ZM | PAN No.: AABCM0541N | CIN No.: L15400GJ1992PLC018759  
Subject to Ahmedabad Jurisdiction



## STATEMENT OF PROFIT AND LOSS for the year ended 31st March, 2025

(Rs. In Lakhs)

	Notes	Year ended March, 31 2026	Year ended March, 31 2025
<b>INCOME</b>			
Revenue from operations	21	50,065.59	42,162.30
Other Income	22	78.12	84.16
<b>Total Income</b>		<b>50,143.72</b>	<b>42,246.46</b>
<b>EXPENSES</b>			
Cost of Materials consumed	23	48,776.77	39,502.46
Purchase of Stock-in-trade		0.43	-
Changes in Inventories Finished Goods, Work -in-progress and stock-in-trade	24	(980.72)	43.12
Employee Benefits expenses	25	236.04	171.10
Finance Cost	26	202.96	226.76
Depreciation, amortization, impairment and obsolescence	5	136.74	131.11
Other Expenses	27	832.91	868.80
<b>Total Expenses</b>		<b>49,205.13</b>	<b>40,943.36</b>
<b>Profit /(loss) before exceptional items and tax (1A - 2A)</b>		<b>938.59</b>	<b>1,303.11</b>
Exceptional item		-	-
<b>Profit / (loss) before tax (3-4)</b>		<b>938.59</b>	<b>1,303.11</b>
Tax Expense			
Current Tax		233.60	330.50
Earlier year tax adjustment		4.74	6.73
Deferred Tax	16	(2.41)	0.86
<b>Total Tax Expense</b>		<b>235.93</b>	<b>338.09</b>
<b>Profit /(loss) for the period (PAT) (5-6)</b>		<b>702.66</b>	<b>965.02</b>
Other Comprehensive Income/(loss)			
<b>Items that will not be reclassified to profit and loss in subsequent periods</b>			
Re-measurement gain / (loss) on defined benefit plans		2.29	0.85
Tax On Above		0.58	0.21
<b>Total Comprehensive Income for the period (7+8)</b>		<b>704.37</b>	<b>965.66</b>
Paid - up equity share capital ( face value of share : Rs 10 each)		575.00	575.00
Earnings per share (EPS) of Rs 10 each ( Not annualised) :			
(a) Basic EPS (Rs.)		12.22	16.78
(b) Diluted EPS (Rs.)		12.22	16.78



Plot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand,  
Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

**GSTIN No.:** 24AABCM0541N1ZM | **PAN No.:** AABCM0541N | **CIN No.:** L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction

CASH FLOW STATEMENT for the year ended 31 March, 2026				
Particulars	For the year ended 31 March, 2026		For the year ended 31 March, 2025	
	In Rs.	In Rs.	In Rs.	In Rs.
<b>A. Cash flow from operating activities</b>				
Net Profit / (Loss) before extraordinary items and tax		938.59		1,303.11
Adjusted For:				
Depreciation and amortisation	136.74		131.11	
Loss on Sale of Fixed Assets				
Finance costs	202.96		276.76	
Interest Income	(1.46)		(7.57)	
Rent Income	(76.37)		(76.29)	
Dividend Income	(0.30)		(0.30)	
Other Income	2.29		0.85	
		263.86		274.56
Operating Profit/(Loss) before working capital changes		1,202.45		1,577.67
Changes in Operating Assets and Liabilities				
(Increase)/Decrease in Inventories	(1,824.34)		(39.64)	
(Increase)/Decrease in Trade receivables	1,010.19		(630.02)	
(Increase)/Decrease in Other current assets	(262.89)		(96.57)	
(Increase)/Decrease in Other Non- current assets	(0.15)		(3.78)	
Increase/(Decrease) in Non Current Provisions	(2.68)		2.76	
Increase/(Decrease) in Trade payables	528.32		(317.06)	
Increase/(Decrease) in Other Current Liabilities	11.40		(16.83)	
Increase/(Decrease) in Provisions	13.16		3.67	
		(526.98)		(1,097.48)
Cash generated from operations		675.47		480.20
Net income tax (paid) / refunds		(379.34)		(262.95)
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>296.14</b>		<b>217.25</b>
<b>B. Cash flow from investing activities</b>				
Inflow :				
Rent Income	76.37		76.29	
Interest Income	1.46		7.57	
Dividend Income	0.30		0.30	
Loans given to Employees recovered			0.25	
Sale of Fixed Assets		78.12		84.41
Outflow :				
Loans and Advances to Employees	(1.51)			
Investment in Fixed Deposit	(0.08)		(0.08)	
Purchase of Fixed Assets	(156.53)		(114.63)	
		(158.12)		(114.71)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(80.00)</b>		<b>(30.29)</b>
<b>C. Cash flow from financing activities</b>				
Inflow :				
Changes in Short Term Borrowings	0.01		73.18	
		0.01		73.18
Outflow :				
Changes in Other Current Financial Liabilities				
Changes in Other Non-Current Liabilities				
Changes in Long Term Borrowings	(3.36)		(27.79)	
Finance Charges	(202.96)		(226.76)	
		(206.31)		(254.55)
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>(206.30)</b>		<b>(181.37)</b>
Net increase/(decrease) in Cash and cash equivalents (A+B+C)		9.84		5.58
Cash and Cash equivalents at the beginning of the year		113.10		107.52
<b>Cash and Cash equivalents at the end of the year</b>		<b>122.94</b>		<b>113.10</b>
Reconciliation of Cash and Cash equivalents with the Balance Sheet				
Cash and cash equivalents as per Balance Sheet		122.94		113.10



PJot No. 351, 353, 358, Opp. Bhagyoday Hotel, Sarkhej - Bavla Highway, Changodar, Ta. Sanand,  
Dist. Ahmedabad - 382213, Gujarat. | P: (02717) 250220 / 221 / 410 | F: (02717) 297123  
E: ambarprotein@gmail.com | W: www.ambarprotein.com

**GSTIN No.:** 24AABCM0541N1ZM | **PAN No.:** AABCM0541N | **CIN No.:** L15400GJ1992PLC018758  
Subject to Ahmedabad Jurisdiction

